Abstract:With each breath we exhale, thousands of molecules are expelled in our breath and each one of us has a 'breathprint' that can tell a lot about his or her state of health. While this may be news to some, it should not be to people in medicine. For one can argue that the field of breath analysis is as old as the field of medicine itself. Hippocrates described fetor oris and fetor hepaticus in his treatise on breath aroma and disease, Lavoisier and Laplace in 1784 showed that respiration consumes oxygen and eliminates carbon dioxide [1], Nebelthau in the mid 1800s showed that diabetics emit breath acetone [2], and Anstie in 1874 isolated ethanol from breath (which is the basis of breath alcohol testing today) [3]. The end of the 20th century and the beginning of the 21st century, however, have arguably witnessed a revolution in our understanding of the constituents of exhaled breath and the development of the field of breath analysis and testing. A major breakthrough in the scientific study of breath started in the 1970s when Linus Pauling demonstrated that there is more to exhaled breath than the classic gases of nitrogen, oxygen, carbon dioxide and water vapor, a lot more. Based on gas–liquid partition chromatography analysis, Linus Pauling reported the presence of 250 substances in exhaled breath [4]. With modern mass spectrometry (MS) and gas chromatography mass spectrometry (GC-MS) instruments, we can now identify more than 1000 unique substances in exhaled breath. These substances include elemental gases like nitric oxide and carbon monoxide and a multitude of volatile organic compounds. Exhaled breath also carries aerosolized droplets collected as 'exhaled breath condensate' that have non-volatile compounds like proteins dissolved in them as well. We now have the technology to test for any and all of these components. Thanks to major breakthroughs in new technologies (infrared, electrochemical, chemiluminescence, and others) and the availability of very sensitive mass spectrometers, the field of breath analysis has made considerable advances in the 21st century. Several methods are now in clinical use or about ready to enter that arena. There are currently commercially available analyzers that can measure NO levels in exhaled breath to the parts per billion (ppb) range and carbon monoxide to the parts per million (ppm) range [5]. Sensitive mass spectrometers can measure volatile compounds on breath down to the parts per trillion (ppt) range. Aerosolized droplets in exhaled breath can be captured by a variety of methods and analyzed for a wide range of biomarkers from metabolic end products to proteins to a variety of cytokines and chemokines, and the possibilities continue to expand [6]. A major hurdle that faced this field as it transitions from the laboratory to clinical testing has been the standardization of sample collection methods. To advance in this area, there had to be a close collaboration between technical experts who typically have a device looking for clinical indication, the medical experts who have the clinical problem looking for a test/biomarker that can be helpful in diagnosis or monitoring, and industry/commercial experts who can build and commercialize the final product. One great example of how the collaboration between technical, medical, and commercial professionals has resulted in a clinically useful tool is the measurement of exhaled nitric oxide (NO) in exhaled breath for monitoring airway inflammation. The advent of chemiluminescence analyzers in the early 1990s allowed the detection of low (ppb) levels of NO in exhaled breath [7]. This was quickly followed by the observation that patients with asthma had higher than normal levels of NO in their exhaled breath that was later linked to eosinophilic airway inflammation [8, 9]. Standardization of the gas collection methods and measurement techniques allowed the industry to build the next generation of analyzers suitable for use in the clinical setting [10, 11]. In 2003 the FDA approved the first desktop NO analyzer for monitoring airway inflammation in asthma [5]. The use of exhaled NO in monitoring asthma is useful for several reasons. It is non-invasive, it can be performed repeatedly, and it can be used in children and patients with severe airflow obstruction where other techniques are difficult or not possible to perform. Exhaled NO may also be more sensitive than currently available tests in detecting airway inflammation, which may allow more optimum therapy [12–19]. As breath analysis offers a window on lung physiology and disease, exhaled breath testing is becoming an increasingly important non-invasive diagnostic method that can be used in the evaluation of health and disease states in the lung and beyond. A few years ago the new International Association of Breath Research (IABR) was established to have a platform for researchers in the field. The association holds an annual meeting and the newly established Journal of Breath Research (JBR) is the official publication of the IABR. In November 2007, the First Breath Analysis Summit/3rd annual meeting of IABR was held on the Cleveland Clinic Campus in Cleveland, Ohio, USA. The Summit brought together industry executives and entrepreneurs with scientists and clinicians to discuss key trends, future directions, and upcoming technologies in breath analysis and medicine. The major focus of the Summit was on medical applications. Topics included exhaled nitric oxide, exhaled breath condensate, electronic nose and sensor arrays, mass spectrometry and bench-top instrumentation, and cutting edge sensor technologies. Medical applications that were covered included asthma, COPD, pulmonary hypertension, other respiratory diseases, gastrointestinal diseases, occupational diseases, critical illness, and cancer. This special issue of JBR contains peer-reviewed, full articles of work presented at the Summit and represents the proceedings of this Summit. References [1] Duveen D I and Klickstein H S 1955 Antoine Laurent Lavoisier's contributions to medicine and public health Bull. Hist. Med. 29 164–79 [2] Hubbard R S 1920 Determination of acetone in expired air J. Biol. Chem. 43 57–65 [3] Baldwin A D 1977 Anstie's alcohol limit: Francis Edmund Anstie 1833–1874 Am. J. Public Health 67 679–81 [4] Pauling L, Robinson A B, Teranishi R and Cary P 1971 Quantitative analysis of urine vapor and breath by gas–liquid partition chromatography Proc. Natl Acad. Sci. USA 68 2374–6 [5] Gill M, Graff G R, Adler A J and Dweik R A 2006 Validation study of fractional exhaled nitric oxide measurements using a handheld monitoring device J. Asthma 43 731–4 [6] Horvath I et al 2005 Exhaled breath condensate: methodological recommendations and unresolved questions Eur. Respir. J. 26 523–48 [7] Gustafsson L E, Leone A M, Persson M G, Wiklund N P and Moncada S 1991 Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans Biochem. Biophys. Res. Commun. 181 852–7 [8] Kharitonov S A, Yates D, Robbins R A, Logan-Sinclair R, Shinebourne E A and Barnes P J 1994 Increased nitric oxide in exhaled air of asthmatic patients Lancet 343 133–5 [9] Persson M G, Zetterstrom O, Agrenius V, Ihre E and Gustafsson L E 1994 Single-breath nitric oxide measurements in asthmatic patients and smokers Lancet 343 146–7 [10] American Thoracic Society 1999 Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children—1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999 Am. J. Respir. Crit. Care Med. 160 2104–17 [11] American Thoracic Society 2005 ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005 Am. J. Respir. Crit. Care Med. 171 912–30 [12] Dweik R A 2001 The promise and reality of nitric oxide in the diagnosis and treatment of lung disease Cleve. Clin. J. Med. 68 486, 488, 490, 493 [13] Dweik R A, Comhair S A, Gaston B, Thunnissen F B, Farver C, Thomassen M J, Kavuru M, Hammel J, Abu-Soud H M and Erzurum S C 2001 NO chemical events in the human airway during the immediate and late antigen-induced asthmatic response Proc. Natl Acad. Sci. USA 98 2622–7 [14] Guo F H, Comhair S A, Zheng S, Dweik R A, Eissa N T, Thomassen M J, Calhoun W and Erzurum S C 2000 Molecular mechanisms of increased nitric oxide (NO) in asthma: evidence for transcriptional and post-translational regulation of NO synthesis J. Immunol. 164 5970–80 [15] Khatri S B, Ozkan M, McCarthy K, Laskowski D, Hammel J, Dweik R A and Erzurum S C 2001 Alterations in exhaled gas profile during allergen-induced asthmatic response Am. J. Respir. Crit. Care Med. 164 1844–8 [16] Khatri S B, Hammel J, Kavuru M S, Erzurum S C and Dweik R A 2003 Temporal association of nitric oxide levels and airflow in asthma after whole lung allergen challenge J. Appl. Physiol. 95 436-40; discussion 435 [17] Dweik R A 2002 Nitric oxide reactions in the asthmatic airway Disease Markers in Exhaled Breath: basic mechanisms and clinical applications (NATO Science Series) ed N Marczin and M H Yacoub (Amsterdam: IOS Press) pp 159–66 [18] Grob N M and Dweik R A 2008 Exhaled nitric oxide in asthma. From diagnosis, to monitoring, to screening: are we there yet? Chest 133 837–9 [19] Ozkan M and Dweik R A 2001 Nitric oxide and airway reactivity Clin. Pulmonary Med. 8 199–206

Abstract:Vyas et al [1] reported that the collection of exhaled breath condensates (EBCs) can be increased 79% by cooling their condenser with dry ice rather than ice water. This was accompanied by what may have been a modest decrease in EBC conductivity and protein concentrations, suggesting that some but not all of the increases in EBC volume were due to the addition of water vapor to the condensate. It is possible that water vapor is trapped more readily than airway droplets at cold temperatures. Alternatively, water vapor in ambient air could have entered through the top of the condenser, which appears to be open to the atmosphere. Despite these decreases in concentration, cold temperatures do appear to increase the rates at which some airway solutes can be collected in the EBC. It should be noted that volatile constituents (e.g., NH4+ and HCO3−), normally account for ~90% of the total conductivity of EBC samples [2–5]. These ions must be removed before measuring conductivity because they are derived primarily from the oral cavity by diffusion. When we originally introduced the conductivity approach [2], the samples were freeze-dried (lyophilized) at < −50 °C and a pressure below 0.133 kPa. Lyophilization removes water molecules from ice (sublimation) rather than liquid water (evaporation). To validate this approach, we showed that more than > 99% of NH4+ in the samples was removed by lyophilization and that the ratios of plasma conductivities to those of lyophilized EBC concentrations were similar to the ratios for 2 other indicators which are used to estimate the dilution of airway droplets by water vapor, namely urea and total cations [2]. In their current study, Vyas et al [1] chose to remove volatiles from their samples by centrifugal evaporation at room temperature and a pressure of 1.3 kPa. They report conductivity values that are approximately an order of magnitude greater than those found when the samples are lyophilized and what would be expected from studies in which urea or total cations are used [2–9]. Since they failed to indicate how much NH4+ remains in their samples after evaporation or measure dilutional indicators other than conductivity, retention of some oral volatiles may have occurred, complicating interpretation of their data. Dry ice failed to significantly change nitrate/nitrite concentrations and this approach may not be particularly useful for measuring these biomarkers. Interconversion between NO3−, NO2− and their derivatives could greatly complicate interpretation of the effect of low temperatures on NO3− and NO2− concentrations in the EBC. Concentrations of hydrogen peroxide doubled when dry ice rather than ice water was used. This may be due in part to increased solubility of H2O2 in cold water. It is probably more appropriate to measure the rates (VE,x moles min–1) at which each of the volatile solutes (for example, x = NH3, CO2, NO2, H2O2) are exhaled from the lungs than to estimate airway fluid concentrations (moles/liter). If most of the exhaled indicator is in the gas phase, VE,x can be calculated from the product of the expiratory flow rate and the fractional concentration of the indicator in the exhaled gas. Furthermore, it would probably be better if the rates of exhalation of volatile indicators were directly measured in the gas phase (e.g., GC-MS after droplet formation is minimized by warming the exhaled air) rather than in condensates. Most volatile substances (including water) are rapidly lost from alveolar and airway surfaces as gases rather than in airway droplets. Because gases readily diffuse between the blood and airspaces in the lungs, exhaled concentrations may reflect concentrations in the blood and extrapulmonary sites of production and may be influenced by local ventilation to perfusion ratios in the lungs. Many factors can affect the efficiency with which different volatiles are collected in condensates including: [1] the air: EBC distribution coefficients and the volume of water in the condenser during condensation, [2] temperature, flow rate and turbulence of air flow through the condenser, [3] the presence of buffers in the lungs, exhaled air and fluid lining the condenser, which is particularly important for weak acids and bases. EBCs cannot be used to estimate losses of volatile solutes from the lungs unless the rates of efflux out of the condenser in both the air and fluid dripping from the condenser are also known. In contrast to nonvolatiles excretion rates of volatiles should not be significantly affected by dilution of airway droplets by condensed water vapor. We would argue that EBC measurements should be largely confined to non-volatile indicators, using a dilutional indicator to estimate concentrations (moles L–1) in the airway fluid. Although excretion of nonvolatile solutes is largely from the airways and is limited by the miniscule volumes of airway fluid in the EBC, estimates of airway concentrations of nonvolatile markers are relatively immune to the multitude of variables listed above and there is no need to measure losses from the condenser. As illustrated in this study, greater cooling could presumably enhance recovery of nonvolatile EBC indicators. Alternatively, droplet formation might be augmented by intentional coughing, depth or rate of respiration, or chest vibration of one sort or another. Salivary contamination should be routinely monitored with sensitive amylase measurements. Of the greatest importance would be the development of sufficiently sensitive assays of EBC biomarkers and dilution. Acknowledgments This work was supported by the National Institutes of Health (grants HL75405 and HD51857). RC occupies the Grancel/Burns Chair in the Rehabilitative Sciences at LA Biomed. References [1] Vyas D et al 2012 The effect of temperature on exhaled breath condensate collection J. Breath Res. 6 036002 [2] Effros R M, Biller J, Foss, B, Hoagland K, Dunning M B, Castillo D, Bosbous M, Sun F and Shaker R 2003 A simple method for estimating respiratory solute dilution in exhaled breath condensates Am. J. Respir. Crit. Care Med. 168 1500–5 [3] Effros R M, Casaburi R, Su J, Dunning M, Torday J, Biller J and Shaker R 2006 The effects of volatile salivary acids and bases on exhaled breath condensate pH Am. J. Respir. Crit. Care Med. 173 386–92 [4] Effros R M, Wahlen K, Bosbous M, Castillo D, Foss B, Dunning M, Gare M, Lin W and Sun F 2002 Dilution of respiratory solutes in exhaled condensates Am. J. Respir. Crit. Care Med. 165 663–9 [5] Effros R M, Peterson B, Casaburi R, Su J, Dunning M, Torday J, Biller J and Shaker R 2005 Epithelial lining fluid solute concentrations in chronic obstructive lung disease patients and normal subjects J. Appl. Physiol. 99 1286–92 [6] Dwyer T M 2004 Sampling airway surface liquid: non-volatiles in the exhaled breath condensate Lung 182 241–50 [7] Baker E H, Clark N, Brennan A L, Fisher D A, Gyl K, Hodson M E, Philips B J, Baines D L and Wood D M 2007 Hyperglycemia and cystic fibrosis alter respiratory fluid glucose concentrations estimated by breath condensate analysis J. Appl. Physiol. 7102 1969–75 [8] Esther C R, Boysen G, Olsen B M, Collins L B, Ghio A J, Swenberg J W and Boucher R C 2009 Mass spectrometric analysis of biomarkers and dilution markers in exhaled breath condensate reveals elevated purines in asthma and cystic fibrosis Am. J. Physiol. Lung. Cell. Mol. Physiol. 296 L987–93 [9] Esther C R, Lazaar A L, Bordonali E, Qaqish B and Boucher R C 2011 Elevated airway purines in COPD Chest 140 954–60

Exhaled Breath Condensate As a Method of Sampling Airway Nitric Oxide and Other Markers of Inflammation.

Exhaled breath analysis: the new frontier in medical testing

Methods of NO detection in exhaled breath

The Role of Exhaled Breath Condensate in Chronic Inflammatory and Neoplastic Diseases of the Respiratory Tract

A new and more accurate technique to characterize airway nitric oxide using different breath-hold times

The Implication of Biomarkers in Exhaled Breath Condensate of Chronic Obstructive Pulmonary Disease

Exhaled Breath Condensate—A Non-Invasive Approach for Diagnostic Methods in Asthma

P-117 ASSESSING EXHALED BREATH CONDENSATE AS MINIMALLY INVASIVE MATRIX FOR LUNG-RELATED BIOMARKER ANALYSES

Exhaled breath condensate (EBC) in respiratory diseases: Recent advances, and future perspectives in the age of Omic sciences

Comment on 'The effect of temperature on exhaled breath condensate collection'

Clinical Significance of Measuring Exhaled Gaseous Signal Molecules

Safety and success of exhaled breath condensate collection in asthma

Clinical Significance of Nitrite/Nitrate, Interleukin-4 and Interferon-gamma in Exhaled Breath Condensate of Asthmatic Patients

Noninvasive Markers of Airway Inflammation in Asthma

Exhaled breath NOx levels in a middle-aged adults population-based study: reference values and association with the smoking status

Biomarkers obtained by non-invasive methods in patients with COPD: where do we stand, what do we expect?

Determination of Biomarkers in Exhaled Breath Condensation of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Its Clinical Implications

The change of nitric oxide in exhaled breath condensate in the diseases of respiratory system

Recent advances in asthma biomarker research

Clinical Application of Exhaled Breath Condensate in Diagnosis of Diseases

Non-volatile organic compounds in exhaled breath particles correspond to active tuberculosis